At a glance Drug / evolocumab (Repatha), a PCSK9-inhibitor biologic antibody Supplement / glutathione (oral, liposomal, or IV forms) Known interaction / none documented in published literature or FDA label Interaction type / not applicable, no shared metabolic pathway identified Evolocumab clearance / proteolytic catabolism, not CYP450 or GSH-dependent Glutathione CYP effect / negligible at typical oral doses (250 to 1,000 mg/day) LDL-C reduction with evolocumab / up to 59% vs
It plays a vital role in cellular detoxification, anti-inflammatory response, disease prevention, and aging reduction
& Ycel, D
Formato oral, em comprimido, s est ainda disponvel nos EUA A Comisso Europeia aprovou uma nova dosagem de manuteno do Wegovy (injeo de semaglutida) de 7,2 mg, trs vezes superior ao mximo existente de 2,4 mg, anunciou a farmacutica dinamarquesa Novo Nordisk